EarningsQ2 2026 Earnings Report
MX:TNDM Q2 2026 EPS Results
Actual EPS-$5.58
Consensus EPS-$5.84
Beat/MissBeat by +$0.25
One Year Ago EPS-$8.76
MX:TNDM Q2 2026 Revenue Results
Actual Revenue$4.62B
Expected Revenue$4.64B
Beat/MissMissed by -$15.45M
YoY Revenue Growth+5.59%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:TNDM Upcoming Earnings
Tandem Diabetes Care's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:TNDM Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: record quarterly sales and shipments, strong international growth, notable gross margin expansion, improving profitability, and clear product and pipeline milestones (Mobi tubeless filing, AdaNet IDE). Near-term challenges include infusion set supplier constraints, a temporary revenue headwind and margin variability from the pharmacy PayGo transition, distributor destocking, and the need to accelerate U.S. new-starts in H2 to meet guidance. On balance, the positives — sizable revenue and margin improvements, product launches, and early PayGo traction — outweigh the near-term operational headwinds, with the company reiterating full-year guidance.Company Guidance
Strong International Growth
International shipments ~11k pumps in Q2, up 19% year-over-year; international sales $75M, up 7% year-over-year (6% in constant currency). Direct channel sales represented ≈13% of revenue, more than double prior year levels.
Material Gross Margin Improvement
Gross margin expanded to 57% in Q2, improving 5 percentage points year-over-year and 2 points sequentially — the second highest gross margin in company history. Management reaffirmed 2026 gross margin guidance of 56%–57%.
Improving Profitability and Cost Discipline
Adjusted EBITDA margin increased to 3% of sales (positive for the fourth consecutive quarter). Operating expenses were $159M and roughly flat year-over-year. Stock-based compensation declined to $16M (6% of sales) from 11% a year ago; full-year SBC guidance reduced to ~$65M from ~$80M previously.
Early Traction with Pharmacy PayGo Program
PayGo (pharmacy) launched in March; in the first full quarter, pharmacy pump shipments represented ~10% of total shipments and pharmacy sales were ~10% of U.S. sales. Company reports ~45% formulary coverage already and higher-than-modeled average monthly ASP for pharmacy supplies (initial data encouraging).
Product and Technology Progress
510(k) submission for Mobi tubeless completed in Q2 (aiming for scaled launch this year pending clearance). CE Mark obtained for pregnancy and adults with type 2 for AID system; Dexcom G7 and FreeStyle Libre 3 integrations expanding; IDE approval for the next-generation AdaNet algorithm granted in Q2, positioning a pivotal trial later this year. New infusion offerings: AutoSoft Plus launched in Canada (July) and SteadySet (7-day wear) in manufacturing scale up.
Reaffirmed Full-Year Guidance
Company reaffirmed 2026 guidance: worldwide sales $1.065B–$1.085B; U.S. $730M–$745M; International $305M–$340M; gross margin 56%–57%; adjusted EBITDA margin 5%–6%.
Record Quarterly Sales and Shipments
Worldwide sales of $255M in Q2, up 6% year-over-year (5% in constant currency); ~33k pumps shipped worldwide, representing the tenth consecutive quarter of record results for the respective sales quarter.
U.S. Performance and New Start Momentum
U.S. sales of $179M, up 5% year-over-year; U.S. pump shipments ~22k, up 7% year-over-year. Q2 new starts were nearly flat year-over-year but improved >20% sequentially from Q1, and new customers from multiple daily injection (MDI) grew mid-single digits and now represent ~70% of new pump starts.
MX:TNDM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed